Hosted on MSN5d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
FiercePharma5d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
STAT5d
Vertex drug for cystic fibrosis wins approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
BioSpace5d
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Monthly Prescribing Reference1d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
Yahoo Finance5d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...
The Boston Globe10d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
The results raised questions about a drug that is key to Vertex diversifying beyond its core cystic fibrosis treatments. Some ...
Mena FN3d
Cystic Fibrosis Market Set For Explosive Growth By 2034, Says Delveinsight
(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...